Evidence map›Paper›PMID 17494078›Full record

ArticleJournal of virology2007

Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections.

Rebecca Pellett Madan, Pedro M M Mesquita, Natalia Cheshenko, Bingwen Jing, Vikas Shende, Esmeralda Guzman, Taylor Heald, Marla J Keller, Steven L Regen, Robin J Shattock and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Novel approaches in fighting herpes simplex virus infections.Expert review of anti-infective therapy · 2009
    Review
  17. Bioconjugate-based molecular umbrellas.Bioconjugate chemistry · 2009
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Rebecca Pellett MadanDepartment of Pediatrics, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
Pedro M M Mesquita
Natalia Cheshenko
Bingwen Jing
Vikas Shende
Esmeralda Guzman
Taylor Heald
Marla J Keller
Steven L Regen
Robin J Shattock
Betsy C Herold
Lehigh University · USSt George's, University of London · GBIcahn School of Medicine at Mount Sinai · US

Funding

Safety of Combination Microbicides in Herpes ModelsU19HD043733 · NICHD · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI HEROLD, BETSY C. · 2002 to 2006
$6.3M
UMBRELLA-LIKE AMPHIPHILESR01GM051814 · NIGMS · LEHIGH UNIVERSITY · PI REGEN, STEVEN L. · 1995 to 2009
$2.8M
Role of Calcium Signaling in HSV-2 InvasionR01AI061679 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI HEROLD, BETSY C. · 2005 to 2009
$1.8M
Role of Calcium Signaling in HSV-2 InvasionR56AI061679 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI HEROLD, BETSY C. · 2010 to 2010
$408k
NIAID NIH HHS AI061679NIAID NIH HHS R01 AI061679NIAID NIH HHS R56 AI061679NICHD NIH HHS HD43733NICHD NIH HHS U19 HD043733NIGMS NIH HHS GM51814NIGMS NIH HHS R01 GM051814
6 · The paper itself

Abstract

Molecular umbrella compounds may function as novel topical microbicides to prevent human immunodeficiency virus (HIV) and herpes simplex virus (HSV) infections. In a preliminary structure-activity investigation, one umbrella compound, designated Spm8CHAS, was identified which inhibited both HIV and HSV infections with no cellular toxicity. The objectives of the current studies were to define its spectrum of antiviral activity, characterize its mechanism of action, and explore the possibility of combining Spm8CHAS with HIV-specific reverse transcriptase inhibitors. Spm8CHAS inhibited infections by laboratory and clinical R5 and X4 clade B and clade C HIV strains in cell culture. Ectocervical tissue explants exposed to HIV-1(BaL) in the presence of Spm8CHAS were completely protected (50% inhibitory concentration [IC(50)], 13.6 microg/ml), and transfer of virus to target T cells via migratory cells was abolished (IC(50), 3.8 microg/ml). Spm8CHAS inhibited HSV-2 infection of epithelial cells 10,000-fold if present throughout the infection. Notably, adding Spm8CHAS to cultures following HSV entry significantly reduced viral infection, indicating that the drug also acts postentry. Subsequent studies indicated that Spm8CHAS blocks cell-to-cell spread of HSV. Confocal microscopy using a fluorescently labeled analog of Spm8CHAS demonstrated that this conjugate crosses the plasma cell membrane and is transported to the nucleus. Combinations of Spm8CHAS with UC-781 or 9-[R-2-(phosphonylmethoxy)propyl] adenine monohydrate in vitro exhibited additive anti-HIV activity with preserved anti-HSV activity. The abilities of Spm8CHAS to inhibit primary isolates of HIV, block HSV infection postentry, and cross cell membranes support the development of a combination microbicide containing Spm8CHAS with an HIV-specific reverse transcriptase inhibitor to prevent both HIV and HSV infections by multiple mechanisms.

Indexed as

Antiviral AgentsCells, CulturedHerpes SimplexHIV InfectionsHumansAntiviral Agents

Identifiers

PMID17494078
PMCPMC1933367
OpenAlexW2143331022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.